Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore

Table 2 Societal Costs (Benefits) Associated with Trastuzumab in the Treatment of HER2neu-positive Early Breast Cancer in Singapore, the United States and Italy

Model		Cost/QALY 2005 US$	Cost (Benefit) 2005 US$	95% CI 2005 US$
Singapore Setting (This study)
	Liberato et al	22,664.75	79.42	16,854.97 to (16,353.79)
	Kurian et al	18,993.70	(3,944.03)	11,295.76 to (22,213.99)
	Garrison et al	15,865.32	(9,263.06)	(227.30) to (12,274.98)
	Sensitivity Analysis
		Lowest Range	10,685.78
		Highest Range	(17,298.79)
United States Setting
	Liberato et al	18,970.00	10,834.07	12,797.05 to (33,982.92)
	Kurian et al	39,982.00	11,729.38	14,901.69 to 7,038.57
	Garrison et al	26,417.00	n/a	n/a
Italian Setting
	Liberato et al	11,984.67	(1,287.63)	14,958.42 to (17,116.39)

Notes to table 2. Values are presented in 2005 US$ (unless otherwise stated) and represents costs (no parenthesis) or benefits (within parenthesis). Societal costs and benefits derived from reference 6. n/a, not available. See text for further details.

ISSN: 1471-2407